- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT02406352
Multispectral Digital Colposcope With Probe for Detection of Cervical Intraepithelial Neoplasia (MDCwProbe)
Development and Application of a Multispectral Digital Colposcope and Probe Algorithm for Detection of Cervical Intraepithelial Neoplasia
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The multispectral digital colposcope (MDC) is a specialized lightsource and imaging device mounted on a custom-made colposcope that acquires a sequence of fluorescence images. This version of the MDC incorporates an upgraded light source, and updates the firmware and the user interface. This results in shorter acquisition times and improved image and spectrum quality control. The MDC also consists of a point probe that is used to take detailed light measurements (call spectroscopy) from smaller regions of the cervix. The goal of the study is to see whether the MDC can perform better than standard methods in detecting cancerous or pre-cancerous abnormalities of the cervix.
Study subjects will be swabbed for detection and typing of the Human Papilloma Virus (HPV). After vinegar is applied on the cervix as per usual colposcopy practice, the MDC will then be used to take a sequence of images of the cervix. Next 2-4 readings will be taken from the cervix using the point probe.
This data will be used to train, test and validate an algorithm specific to the MDC. The ability of the algorithm to detect cervical intraepithelial neoplasia will be compared to standard clinical care (colposcopy).
The MDC images and pathology results will be compared to the spectroscopy data from the MDC probe. The investigators will determine if spectroscopy has equal sensitivity to colposcopy for detecting high grade lesions.
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Leonid Fradkin, PhD
- Telefonnummer: 718-240-8225
- E-mail: lfradkin@bhmcny.org
Undersøgelse Kontakt Backup
- Navn: Thelma Carrillo, MPH
- Telefonnummer: 718-240-5978
- E-mail: tcarrill@bhmcny.org
Studiesteder
-
-
New York
-
Brooklyn, New York, Forenede Stater, 11212
- Rekruttering
- Brookdale University Hospital and Medical Center
-
Kontakt:
- Leonid Fradkin, PhD
- Telefonnummer: 718-240-8225
- E-mail: lfradkin@bhmcny.org
-
Kontakt:
- Thelma Carrillo, MPH
- Telefonnummer: 718-240-5978
- E-mail: tcarrill@bhmcny.org
-
Ledende efterforsker:
- Michele Follen, MD, PhD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Women who are at least 18 years old
- Are not pregnant (negative urine test) or breastfeeding
- Referred for colposcopy or LEEP treatment
- Can provide written informed consent
Exclusion Criteria:
- Women who do not meet the inclusion criteria
- Women who have had a hysterectomy
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Diagnostisk
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: Routine colposcopy and MDC with probe
The intervention which consists of obtaining cervical images with the MDC and spectroscopic data with the probe will be applied to all participants who agreed to participate in the study during their visit for a colposcopy exam or treatment with a LEEP procedure.
A control biopsy will also be obtained from patients who agree to provide it.
The control biopsy is a biopsy of cervical tissue that does not appear to have atypical changes when observed through a standard of care colposcope.
|
Cervical images will be obtained with the Multispectral Digital Colposcope. Spectroscopic data will be obtained with the probe from eligible patients who provided consent to participate in the study. The standard of care for research participants will not change. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Detection of precancerous cervical lesions or cervical cancer
Tidsramme: At point of care for colposcopy or treatment with LEEP (5 minutes).
|
Eligible patients who are referred to the colposcopy clinic for a diagnosis following an abnormal Pap smear will be asked to participate in the study. All participating women will receive their standard of care colposcopy as usual. In addition to their routine care, the MDC with probe will also be used to collect images of the cervix and spectroscopic measurements with the probe. All measurements will be compared with the biopsies obtained. The MDC with probe will not be used to determine from where the biopsies need to be obtained. One or two additional biopsies will be obtained from tissue that appears to be unaffected. These will be the control biopsies. Patients may refuse to provide the additional biopsies which are not part of the standard of care. Patients scheduled for a treatment with the Loop Electrosurgical Excision Procedure (LEEP) will be asked for consent to obtain one or two biopsies prior to the LEEP procedure, but after anesthesia has been applied. |
At point of care for colposcopy or treatment with LEEP (5 minutes).
|
Samarbejdspartnere og efterforskere
Efterforskere
- Ledende efterforsker: Michele Follen, MD, PhD, Brookdale University Hospital and Medical Center
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Forventet)
Studieafslutning (Forventet)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 14-35
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Carcinom in situ af livmoderhalsen
-
Mithra PharmaceuticalsAfsluttetCervix intraepitelial neoplasi | Uterin cervikal neoplasiBelgien
-
Liao NingRekrutteringBrystneoplasmerKina
-
Sunnybrook Health Sciences CentreUniversity of Toronto; Sunnybrook Research InstituteAfsluttetRectal Neoplasma Carcinoma in Situ AdenocarcinomaCanada
-
SamanTree Medical SASt. Vincenz Krankenhaus GmbH, PaderbornAfsluttetBrystbevarende kirurgi | Brystkræft - Ductal Carcinoma in Situ (DCIS)Tyskland
-
Elizabeth J FranzmannAveta Biomics, Inc.RekrutteringOrofaryngeal dysplasi | Mundhule dysplasi | Oral carcinoma in situForenede Stater
-
University of AarhusAfsluttetCervikal dysplasi | Cervikal læsion | Cervix sygdomDanmark
-
The First Affiliated Hospital of Henan University...Ikke rekrutterer endnuEsophageal Carcinoma in Situ AJCC V7
-
Barretos Cancer HospitalAfsluttetCervikal intraepitelial neoplasi | Cervix NeoplasmaBrasilien
-
University of FlorenceCareggi Hospital; University of Milano Bicocca; Fondazione C.N.R./Regione...RekrutteringBlærekræft | Urothelial carcinom blære | Urothelialt karcinom | Urothelial neoplasma | Urothelial carcinoma in situItalien
-
Hiantis SrlSciensano; Genefirst LTDAfsluttetNeoplasmer | Neoplasmer efter histologisk type | Karcinom in situ | Neoplasma cervix | Cervikal Intraepitelial Neoplasi Grad 2/3 | Karcinom livmoderhalsen livmoderItalien, Irland, Det Forenede Kongerige